Global biotech leader CSL has awarded seven Greater Chicago Area students with scholarships totaling more than $20,000. As part of the company’s new Promising Futures Scholarship Program, CSL has awarded 37 scholarships in total to-date to U.S.-based CSL employees and their dependents.
“Our scholarship recipients are already making a difference in the world, through their volunteerism and community involvement,” said CSL Chief Human Resources Officer Elizabeth Walker. “It’s extremely rewarding to know that CSL’s support will help them and their families, as they strive to continue achieving their educational goals and ambitions.”
The program, which is in its first year, is designed to provide financial assistance to employees and their dependents to help cover the cost of attending technical school, vocational school, a two-to four-year college or other advanced education.
“I am sincerely honored to have been selected as one of the recipients of the CSL Promising Futures Scholarship Program,” said Paul Williams III of Bourbonnais, who is studying to be an electrical engineering technician at Kankakee Community College. “I know that [CSL] believes in student development and empowerment. This prestigious award will help me pursue my educational ambitions and enhance my skills and capabilities.”
Part of the company’s commitment to diversity, equity & inclusion, the scholarships are intended to support students who are part of a diverse community underrepresented in the biotechnology industry, have overcome one or more substantial obstacles in pursuing their studies or training, and/or are first-generation college students.
All seven Greater Chicago Area scholarship recipients are children of parents who work for either CSL Behring or its subsidiary, CSL Plasma.
CSL (ASX:CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our two businesses, CSL Behring and Seqirus – provides lifesaving products to patients in more than 100 countries and employs more than 25,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSLBehring.com/Vita and follow us on Twitter.com/CSL.
For more information about CSL Limited, visit www.csl.com